Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RNAi therapeutics - Alexion AstraZencea Rare Disease/Dicerna Pharmaceuticals

Next Previous
Search
Drug Profile

Research programme: RNAi therapeutics - Alexion AstraZencea Rare Disease/Dicerna Pharmaceuticals

Alternative Names: DCR-COMP3; DCR-COMP4; GalXC RNAi molecules

Latest Information Update: 28 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexion Pharmaceuticals; Dicerna Pharmaceuticals
  • Developer Alexion AstraZeneca Rare Disease; Dicerna Pharmaceuticals
  • Class Hepatoprotectants; Small interfering RNA
  • Mechanism of Action Complement activation inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Liver disorders

Most Recent Events

  • 28 Nov 2022 No recent reports of development identified for preclinical development in Liver-disorders in USA (SC)
  • 28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk
  • 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top